KARL NÄGLER, PH.D.

Partner at Gimv

Dr. Nägler joined Gimv’s as a Partner in 2011. He began his professional career in 2002 at Atlas Venture in London and Munich, and later joined Ventech, a Paris-based venture capital firm.

Dr.  Nägler was instrumental in the formation, financing and/or exit of several European start-ups including U3 Pharma (acquired by Daiichi Sankyo) and Nitec Pharma (acquired by Horizon Pharma). He also led investments in Prosonix (acquired by Circassia), Covagen (acquired by Johnson & Johnson), Biom’up (EPA:BUP), Topas Therapeutics, Imcheck Therapeutics and Camel-IDS, and has represented Gimv on the boards of those companies, as well as at Actogenix (acquired by Intrexon).

Dr. Nägler was a Scientific Fellow at CNRS for Neurochemistry in Strasbourg, France. He earned his Ph.D. in Molecular Neurobiology from Max-Delbrück-Center for Molecular Medicine, Berlin and a Diploma in Biology from Free University of Berlin.